Pharmaceutical Water Systems: Purified Water, WFI and the EMA Guideline

Water is the most widely used excipient and cleaning agent in pharmaceutical manufacturing, and the system that produces it is one of the first places an inspector looks. Choosing the wrong grade, or running the right grade badly, is a common route to findings.

Which grade for which product

The EMA guideline on the quality of water for pharmaceutical use, which took effect on 1 February 2021 and applies to new applications and relevant variations, sets out where each grade is expected.

  • Purified Water is generally acceptable for medicines that do not need to be both sterile and apyrogenic, such as oral and many cutaneous preparations.
  • Water for Injections (WFI) is expected for parenteral products, biologicals including vaccines and ATMPs, and certain other categories such as irrigation and peritoneal dialysis solutions.
  • For active substances, WFI is expected only where the substance is sterile and apyrogenic, or for certain ATMP steps.

The dossier should justify the grade used at each manufacturing stage on a risk basis.

How WFI may be produced

Since the revised Ph. Eur. monograph for WFI took effect on 1 April 2017, WFI may be produced by distillation or by a purification process equivalent to distillation, for example reverse osmosis combined with electrodeionisation, ultrafiltration or nanofiltration. The guideline asks manufacturers to notify their GMP supervisory authority before introducing reverse osmosis at a site. A non-distillation system is not a cost shortcut: its microbial control depends heavily on design, sanitisation and monitoring.

What inspectors look at

The guideline stresses that microbiological control is the main concern and that validation and qualification of purification, storage and distribution are central to GMP inspections. In practice this means:

  • Design that avoids dead legs and supports drainage and sanitisation, whether hot, chemical or ozone.
  • A qualification that covers more than one season of supply water quality.
  • Sampling points, frequencies and alert and action levels justified from data, with trending and not just compliance with the pharmacopoeial limits.
  • Control of change, because a new membrane, a modified loop or a repaired valve can alter system behaviour.

Common weaknesses

Typical findings include unqualified points of use, trending that stops at the limit, investigations that close with no root cause, and documentation that does not link water excursions to product impact. Water used for cleaning and final rinse deserves the same attention as water used in the formulation.

Documentation to have ready

Keep the system description, qualification reports, sampling plans, alert and action level rationale, monthly and annual trend summaries and the link to the change control process in one traceable place. A change to a loop, a membrane or a sanitisation regime should always prompt a documented decision on whether requalification is needed. For veterinary manufacturers, the same expectations apply under the veterinary GMP rules that now apply.

How PQRA helps

PQRA can review your water grade justification for the dossier, assess an existing system against the EMA guideline and the pharmacopoeial monographs, and prepare validation and monitoring documentation for inspection. We work with both human and veterinary manufacturers.

Contact PQRA to discuss your water system strategy or an upcoming inspection.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *